Acta Haematologica[JOURNAL]
Sun
200 papers
AI Applications in Transfusion Medicine: Opportunities, Challenges, and Future Directions.
Barzilai M, Cohen O
Acta Haematol · 2025 · PMID 40349705 · Full text
<p>Background: Artificial intelligence (AI) is reshaping healthcare, with its applications in transfusion medicine (TM) showing great promise to address longstanding challenges. Summary: This review explores the integrat...
<p>Background: Artificial intelligence (AI) is reshaping healthcare, with its applications in transfusion medicine (TM) showing great promise to address longstanding challenges. Summary: This review explores the integration of AI-driven tools, including machine learning, deep learning, natural language processing, and predictive analytics, across various domains of TM. From enhancing donor management and optimizing blood product quality to predicting transfusion needs and assessing bleeding risks, AI has demonstrated its potential to improve operational efficiency, patient safety, and resource allocation. Additionally, AI-powered systems enable more accurate blood antigen phenotyping, automate hemovigilance workflows, and streamline inventory management through advanced forecasting models. While these advancements are largely exploratory, early studies highlight the growing importance of AI in improving patient outcomes and advancing precision medicine. However, challenges such as variability in clinical workflows, algorithmic transparency, equitable access, and ethical concerns around data privacy and bias must be addressed to ensure responsible integration. Key Messages: (i) AI-driven tools are being applied across multiple domains of TM. (ii) Early studies demonstrate the potential for AI to improve efficiency, safety, and personalization. (iii) Key implementation challenges include data privacy, workflow integration, and equitable access. </p>.
Beyond Cellular Therapies: The Expanding Role of Antibody-Driven Immunotherapy in Pediatric Acute Lymphoblastic Leukemia.
McCall D, Catueno S, Ramakrishnan R … +6 more , Tewari P, Sheikh I, Gibson A, Nuñez CA, Garcia MB, Cuglievan B
Acta Haematol · 2026 · PMID 40324358 · Publisher ↗
BACKGROUND: The integration of novel antibody-mediated targeted therapies into both relapsed/refractory (R/R) and frontline pediatric acute lymphoblastic leukemia (ALL) treatment protocols has led to critical advancement...
BACKGROUND: The integration of novel antibody-mediated targeted therapies into both relapsed/refractory (R/R) and frontline pediatric acute lymphoblastic leukemia (ALL) treatment protocols has led to critical advancements in the field. Current research efforts focus on optimizing targeted therapies to enhance precision and efficacy while minimizing toxicity by reducing chemotherapy. A notable example is the addition of blinatumomab, demonstrating superiority over conventional chemotherapy, with an 8% increase in disease-free survival at an interim analysis, reaching 96%. Inotuzumab ozogamicin (InO) has also shown promise, achieving nearly a 70% complete response rate in pediatric R/R B-cell ALL (B-ALL) trials. Additionally, daratumumab in T-cell ALL (T-ALL) and chimeric antigen receptor T-cell therapies, particularly CD19-directed (B-ALL) and CD7-directed (T-ALL) strategies, are under active investigation. SUMMARY: This review will provide an overview of targeted antibody-mediated immunotherapies in both B-ALL and T-ALL, with a focus on their pediatric applications, supporting data, and future prospects. KEY MESSAGES: The next cycle of frontline trials in pediatric ALL will incorporate more immunotherapy with reduction of chemotherapy. Subsequent trials will utilize more concurrent chemoimmunotherapy blocks as precision testing and risk-adapted therapy will continue to develop. These advancements reflect a paradigm shift toward more precise, less toxic treatment strategies in pediatric ALL.
Favorable Rates of Cardiovascular Events with Stringent Cardiovascular Monitoring and a Lowered Dose of Ponatinib as Second-Line Treatment in Chronic Phase Chronic Myeloid Leukemia Patients Failing or Intolerant to First-Line Second-Generation Tyrosine Kinase Inhibitor Treatment: Results of the Prospective PONS Trial.
le Coutre P, Burchert A, Saußele S … +10 more , Schwarzer T, Stintzing S, Pelzer U, Bullinger L, Elmaagacli A, Jehn C, Stegelmann F, Hochhaus A, Ernst T, Göthert JR
Acta Haematol · 2026 · PMID 40324350 · Publisher ↗
INTRODUCTION: In chronic myeloid leukemia patients, second-line treatment requires careful consideration of response and tolerability. As most patients need a more efficient tyrosine kinase inhibitor, ponatinib at a lowe...
INTRODUCTION: In chronic myeloid leukemia patients, second-line treatment requires careful consideration of response and tolerability. As most patients need a more efficient tyrosine kinase inhibitor, ponatinib at a lowered dose should be evaluated in this setting. METHODS: We studied a lowered dose of 30 mg ponatinib in second line in patients selected toward a low cardiovascular risk. In 22 screened patients, ponatinib was started in 18 patients previously treated with imatinib (n = 3), dasatinib (n = 9), or nilotinib (n = 6). Patients were frequently monitored for cardiovascular toxicities by testing of blood pressure, vital signs, ankle brachial index or duplex, oral glucose tolerance test, echocardiography, ECG, and fundoscopy. The study protocol allowed dose reductions in patients achieving MMR. Both previously resistant or intolerant patients were recruited. RESULTS: No serious cardiovascular events were observed, and low-grade cardiovascular toxicity was negligible. By 12 months, 13 patients (92.9%) were in complete hematologic remission, 10 patients (55.6%) were in MMR, and 5 patients (27.8%) were in MR4. Most importantly, we demonstrated that thorough monitoring of cardiovascular risk is feasible. CONCLUSIONS: We demonstrated that a lowered dose of 30 mg ponatinib in selected patients can be maintained without serious cardiovascular complications, provided cardiovascular risk monitoring is performed. In our patient cohort, this approach resulted in favorable response rates.
Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit/Older AML Patients.
Mayer K, Birk L, Schwab K … +5 more , Schmidt-Wolf IGH, von Lilienfeld-Toal M, Brossart P, Glasmacher A, Hahn-Ast C
Acta Haematol · 2026 · PMID 40324345 · Publisher ↗
INTRODUCTION: The standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) is 7 days cytarabine and 3 days daunorubicin. However, older and frail patients cannot be treated intensively. Before hypo...
INTRODUCTION: The standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) is 7 days cytarabine and 3 days daunorubicin. However, older and frail patients cannot be treated intensively. Before hypomethylating agents (HMA) plus venetoclax (VEN) was established we formulated a more tolerable induction therapy for these patients using continuous infusions of reduced doses of cytarabine (A) and idarubicin (IDA) in combination with ATRA (A), the (A)-AIDA regimen and trying to reach noteworthy and relevant remission rates with acceptable toxicities in this special population. METHODS: Between 1998 and 2015 older/frail patients with newly diagnosed or relapsed AML received (A)-AIDA. Treatment consisted of cytarabine 100 mg/m2/d d1-5 and IDA 5 mg/m2/d d1-5 as continuous infusion. Since 2003 ATRA (45 mg/m2/d d4-6, 15 mg/m2/d d7-28) was added in some patients. RESULTS: 154 patients received (A)-AIDA, median age was 71 years. In 40% the AML was secondary, 15.6% had relapsed AML. The complete remission rate was 41%, 7% reached a partial remission, the median overall survival was 7 months. No significant differences of remission rates regarding various known risk factors for outcome with (A)-AIDA were detected. CONLUSION: Recent studies established HMA/VEN as first-line treatment for older/frail AML patients. Because (A)-AIDA is equally effective in patients with secondary or relapsed AML or ECOG >1, this regimen is an interesting treatment option for patients uneligible to HMA/VEN regimens.
[PharmaNews].
Acta Haematol · 2025 · PMID 40300571 · Publisher ↗
Abstract loading — click title to view on PubMed.
Emicizumab and Acquired Hemophilia A Secondary to Multiple Myeloma.
Cuschera F, Vekemans MC, Hermans C
Acta Haematol · 2026 · PMID 40273904 · Publisher ↗
INTRODUCTION: Acquired hemophilia A (AHA) is a severe bleeding disorder, sometimes linked to plasma cell dyscrasias. In this context, emicizumab, a bispecific antibody, provides stable hemostasis by mimicking factor VIII...
INTRODUCTION: Acquired hemophilia A (AHA) is a severe bleeding disorder, sometimes linked to plasma cell dyscrasias. In this context, emicizumab, a bispecific antibody, provides stable hemostasis by mimicking factor VIII (FVIII), offering convenience and flexibility compared to bypassing agents. Moreover, targeted anti-myeloma therapy directly addresses the underlying plasma cell disorder, potentially achieving better and more durable control of AHA than conventional immunosuppressive therapy, while reducing its associated adverse effects. CASE PRESENTATION: We describe the successful management of AHA secondary to multiple myeloma (MM) using emicizumab and targeted anti-myeloma therapy. The patient initially responded to bortezomib-dexamethasone but required teclistamab due to disease progression. Emicizumab maintained hemostatic stability, allowing time for effective MM management. CONCLUSION: Emicizumab, in conjunction with targeted myeloma treatment, represents a promising strategy to improve outcomes for AHA patients with MM. This approach is particularly advantageous for older patients with multiple comorbidities, who face elevated risks of thrombotic, bleeding, and infectious complications.
Concordance between Tympanic and Enteral Temperature for Early Fever Detection in Hematologic Intensive Care Unit Patients: A Prospective Study.
Bouclet F, Pénichoux J, Mihailescu SD … +21 more , Seris S, Burel L, Richard D, Collard S, Jennet E, Bertrand E, Alani M, Dubois S, Ménard AL, Camus V, Stamatoullas A, Lenain P, Contentin N, Leprêtre S, Tilly H, Lemasle E, Lanic H, Daouphars M, Pépin LF, Moussay S, Jardin F
Acta Haematol · 2026 · PMID 40262543 · Publisher ↗
INTRODUCTION: Early detection of fever is crucial in neutropenic patients. Lack of precision in body temperature measurement can occur with peripheral site measurements. Furthermore, intermittent temperature monitoring m...
INTRODUCTION: Early detection of fever is crucial in neutropenic patients. Lack of precision in body temperature measurement can occur with peripheral site measurements. Furthermore, intermittent temperature monitoring may result in a delay in fever detection. METHODS: We conducted a prospective study in hematologic intensive care unit (HICU) patients receiving autologous stem cell transplant or intensive chemotherapy in order to compare tympanic and enteral temperature measured by an ingested electronic pill (BodyCap®, France). RESULTS: Twenty-six patients ingested at least one capsule with a total of 218 days of tympanic and enteral simultaneous measurement. In 12% of these measurements, we identified a difference over 0.5°C between the left ear versus right ear measurements. Enteral temperature was usually higher than the tympanic one (p < 0.0001) with 14% of the measurements that were discordant with higher enteral temperature and 1.9% that were discordant with higher tympanic temperature. Febrile episodes were detected with the ingestible pill on average almost 24 h earlier than with the tympanic measurement. Early capsule evacuation occurred in 20.4% of the cases, mainly because of diarrhea, a frequent adverse event in these patients. Patients were satisfied with capsule ingestion according to a questionnaire. CONCLUSION: In this prospective trial (TEMPET), we demonstrated that enteral temperature measured by an ingested pill is feasible in HICU and detects fever earlier than tympanic routine measurements. Digestive symptoms related to hematological disease and/or treatments are limiting factors for its generalized usage.
Epiglottitis in Patients Treated for Acute Leukemia: Case Series and Systematic Review of the Literature.
Sherban A, Frisch A, Rozenthal A … +8 more , Buchrits S, Atamna B, Ben-Ner D, Eden S, Atamna A, Ofran Y, Raanani P, Wolach O
Acta Haematol · 2026 · PMID 40245848 · Full text
<p>Introduction: Acute epiglottitis is a medical emergency characterized by inflammation of supraglottic structures of the larynx and epiglottis. The clinical characteristics and course of this complication in acute leuk...
<p>Introduction: Acute epiglottitis is a medical emergency characterized by inflammation of supraglottic structures of the larynx and epiglottis. The clinical characteristics and course of this complication in acute leukemia (AL) are largely unknown. We present a case series and a systematic review of the literature of adult patients with AL and acute epiglottitis. Case Presentation: Four patients with acute myeloid leukemia (age 38-61 years) were diagnosed with acute epiglottitis during their intensive treatment course. One patient presented with epiglottitis at the end of induction, two at the end of consolidation therapy, and 1 patient presented with a later event. Three patients were in grade 4 neutropenia during infection onset (median aplasia duration to event 9 [range 4-14] days). All patients presented with neck pain and dysphagia and 2 patients also had dyspnea at presentation. Urgent invasive airway protection was required in 3 patients. Two patients died due to this complication, one suffered anoxic brain injury. A systematic literature review identified 8 additional cases of epiglottitis. Conclusion: Acute epiglottis is a rare but significant medical emergency with unique challenges in the setting of AL that is caused by atypical infectious pathogens. Early detection and a multidisciplinary therapeutic effort are crucial to improve patient outcome. </p>.
Global, Regional, and National Burden of Leukemia (1990-2021): A Systematic Analysis for the Global Burden of Disease Study 2021.
Yao X, Wang H, Yang L
Acta Haematol · 2026 · PMID 40228492 · Publisher ↗
INTRODUCTION: Leukemia is a group of diseases caused by malignant hematopoietic stem cell clones. Leukemia ranks 13th in incidence and 10th in mortality, according to the Global Cancer Statistics 2022. METHODS: We comput...
INTRODUCTION: Leukemia is a group of diseases caused by malignant hematopoietic stem cell clones. Leukemia ranks 13th in incidence and 10th in mortality, according to the Global Cancer Statistics 2022. METHODS: We computed the prevalence, incidence, mortality, and disability-adjusted life years (DALYs) using the Global Burden of Disease (GBD) 2021 data. We rigorously tested the time trend from 1990 to 2021 using Joinpoint regression analysis. This method facilitates the calculation of annual percentage change (APC), average annual percentage change, and 95% confidence interval (CI). RESULTS: In 2021, the age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate of leukemia were 21.07 per 100,000 people (95% CI: 17.65-23.61), 5.63 per 100,000 people (95% CI: 4.83-6.17), 3.89 per 100,000 people (95% CI: 3.34-4.25), and 136.94 per 100,000 people (95% CI: 111.89-153.71), respectively. These figures have been obtained globally. Gender comparisons show that men have a higher burden of disease. The 90-94 age-group has the highest global prevalence of leukemia, with the prevalence increasing with age. Age-standardized DALYs rates, ASMR, and ASIR demonstrated a general declining trend from 1990 to 2021. The results of the Joinpoint analysis showed that between 2019 and 2021, there was a drop in the global ASPR (APC = -2.68%; 95% CI: -4.76% to -0.54%; p = 0.017), ASIR (APC = -2.46%; 95% CI: -3.33% to -1.59%; p < 0.001), and ASMR (APC = -1.87%; 95% CI: -2.75% to -0.99%; p < 0.001). CONCLUSION: The results indicated an overall decrease in the burden of leukemia. These results provide important epidemiological data for the development of novel treatments.
Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia - Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis.
Zeidan AM, Yu R, Wang Y … +8 more , Lan Z, Grinblatt DL, Elsouda D, Spalding J, Block A, Touya M, Walker MS, Pandya BJ
Acta Haematol · 2026 · PMID 40228486 · Full text
UNLABELLED: <p>Introduction: Recent advances in genomic research have expanded the treatment landscape for acute myeloid leukemia (AML). This study examined treatment patterns and clinical outcomes among relapsed/refract...
UNLABELLED: <p>Introduction: Recent advances in genomic research have expanded the treatment landscape for acute myeloid leukemia (AML). This study examined treatment patterns and clinical outcomes among relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-mutated AML patients. METHODS: This retrospective longitudinal study included patients with confirmed AML diagnosis, FLT3 mutation, and 1st R/R event from 1/1/2015 to 1/31/2023 in the ConcertAI Oncology Dataset. Treatment patterns, FLT3 testing rates, real-world overall survival (rwOS), and real-world time to next treatment (rwTTNT) were studied. RESULTS: Among the 336 treated patients, 50.6% received FLT3-tyrosine kinase inhibitors (FLT3-TKIs) as first treatment after R/R event, of which 51.8% received gilteritinib. High-intensity chemotherapy used as first treatment after R/R event decreased from 67.9% in 2015 to 20.0% in 2022, while FLT3-TKI utilization rose to 50% over the same period. Among the 246 patients tested for FLT3 at initial AML diagnosis, only 36% were retested at 1st R/R event. Median rwOS and rwTTNT among FLT3-TKI patients were 12.4 months and 2.9 months, respectively. CONCLUSION: This study reveals a trend toward increasing FLT3-TKI use and highlights the need for repeated FLT3 testing among R/R AML patients. Real-world evidence is vital in understanding R/R AML patient care amidst emerging therapies. </p>.
Tucidinostat Combined with Bortezomib, Liposomal Doxorubicin, and Dexamethasone in Multiple Myeloma Treatment.
Bi J, Dou X, Liang R … +8 more , Wen L, Liu Y, Lei X, Wang L, Guo H, Huang X, Wang M, Lu J
Acta Haematol · 2026 · PMID 40222360 · Publisher ↗
INTRODUCTION: We conducted a single-arm, open-label dose-exploration study to evaluate the safety and efficacy of the histone deacetylase inhibitor tucidinostat combined with bortezomib, liposomal doxorubicin, and dexame...
INTRODUCTION: We conducted a single-arm, open-label dose-exploration study to evaluate the safety and efficacy of the histone deacetylase inhibitor tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone (C-PDD) in treating relapsed and refractory multiple myeloma (RRMM) patients. METHODS: Eighteen patients were enrolled from August 2020 to May 2021, receiving 21-day cycles of C-PDD. RESULTS: Eighteen cases were analysed, with a median prior treatment line of 2 (range: 1-4). The median number of completed treatment cycles was 4 (range: 1-8). The overall response rate was 57%, including 14% complete response, 14% very good partial response, and 29% partial response. Both bortezomib-sensitive and refractory groups had a response rate of 57%. The response rate was 100% in patients with extramedullary extraosseous involvement. The median follow-up was 42 months (range: 3-44), with median progression-free survival of 7 months and median overall survival of 24.5 months. Grade 3-4 haematologic adverse events included thrombocytopaenia (50%), neutropenia (33%), and anaemia (33%). Non-haematologic adverse events were mostly grade 1-2, with 1 case of grade 3 peripheral sensory neuropathy. CONCLUSION: The C-PDD regimen showed efficacy in RRMM, including bortezomib-refractory disease and EME patients. The optimal dose and combination need to be explored in the future.
Recombinant Myeloid Hematopoietic Growth Factors and Clinical Stimulation of Acute Myeloid Leukemia Cells: A Narrative Review.
Gilbert JS, Pollyea DA, Walsh TJ … +2 more , Groll AH, Lazarus HM
Acta Haematol · 2026 · PMID 40199260 · Publisher ↗
BACKGROUND: The advent of molecularly cloned hematopoietic growth factors (rhuG-CSF and rhuGM-CSF) enhanced the safety in treating acute myeloid leukemia (AML) by reducing the duration of neutropenia and thus decreasing...
BACKGROUND: The advent of molecularly cloned hematopoietic growth factors (rhuG-CSF and rhuGM-CSF) enhanced the safety in treating acute myeloid leukemia (AML) by reducing the duration of neutropenia and thus decreasing the risks for infection. However, early in vitro studies demonstrated leukemia cell proliferation in response to these agents, raising reasonable concerns related to whether these factors can cause or contribute to relapse or progression of AML. SUMMARY: Clinical studies using recombinant myeloid hematopoietic growth factors have supported their safety, as there is little or no clear evidence for an association with an increased risk of relapse in AML in patients, regardless of the hematopoietic growth factor used, or whether the setting of AML is newly diagnosed or relapsed/refractory. One exception may be in the pediatric population, though this effect might reflect a different isoform of the G-CSF receptor expressed on the AML cells, as this truncated receptor is also seen in severe congenital neutropenia and aplastic anemia and underlies the increased myeloid malignancies that develop in these diseases after long-term exposure to growth factors. KEY MESSAGES: The current data support the use of rhuG-CSF and rhuGM-CSF in most patient populations with AML. Future studies should explore the factors influencing hematopoietic growth factor sensitivity in AML subpopulations to guide therapeutic decisions.
Artificial Intelligence and Venous Thromboembolism: A Narrative Review of Applications, Benefits, and Limitations.
Mudrik A, Mudrik A, Efros O
Acta Haematol · 2025 · PMID 40199255 · Full text
<p>Background: Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, remains a leading cause of cardiovascular morbidity and mortality. Artificial intelligence (AI) holds promise for potent...
<p>Background: Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, remains a leading cause of cardiovascular morbidity and mortality. Artificial intelligence (AI) holds promise for potential improvement of risk stratification, diagnosis, and management of VTE. Summary: This narrative review explores the applications, benefits, and limitations of AI in VTE management. AI models were shown to outperform conventional methods in identifying high-risk candidates for VTE prophylaxis treatments in several postsurgical settings. It has also been demonstrated to be efficient in the early detection of VTE events, particularly through point-of-care AI-guided sonography and computer tomography image processing. Data biases, model transparency, and the need for regulatory frameworks remain significant limitations in the full integration of AI into clinical practice. Key Messages: AI has the potential to improve VTE care by enhancing risk stratification and diagnosis. The integration of AI-driven models into clinical workflows has the potential to reduce costs, streamline diagnostic processes, and ensure effective management of VTE. Safe and effective integration of AI into VTE care requires addressing its limitations, such as interpretability, privacy, and algorithmic bias. </p>.
Prevalence of Pre-Treatment Sarcopenia in Patients Newly Diagnosed with Lymphoma.
Grønset CN, Jarden M, Christensen J … +3 more , Hutchings M, Tolver A, Suetta C
Acta Haematol · 2026 · PMID 40188813 · Publisher ↗
INTRODUCTION: Sarcopenia, defined by reduced muscle strength, mass, and performance, presents a significant challenge in cancer care due to its impact on treatment outcomes, quality of life, and survival. This study aime...
INTRODUCTION: Sarcopenia, defined by reduced muscle strength, mass, and performance, presents a significant challenge in cancer care due to its impact on treatment outcomes, quality of life, and survival. This study aimed to assess its prevalence in newly diagnosed lymphoma patients. METHODS: Adults planned for first-line anthracycline-based chemotherapy were enrolled and screened for sarcopenia before treatment. Sarcopenia was defined by the European guidelines (EWGSOP2) using low muscle strength (hand-grip), low muscle mass (DXA), and low physical performance (gait speed). RESULTS: Sixty-nine patients (mean age 57, 19 women) were included. Six patients (9%) had low hand-grip strength, 15 (22%) had low muscle mass, and 4 (6%) demonstrated low gait speed. Two patients met the criteria for sarcopenia, with one having severe sarcopenia. CONCLUSION: Sarcopenia prevalence was 3%, but 22% had low muscle mass, suggesting muscle strength alone may not be an optimal screening tool for lymphoma patients.
Acute Promyelocytic Leukemia Presenting with Cranial Nerve Involvement and Clivus Mass.
Nanduri AC, Ashraf F, Hlaing SS … +4 more , Brister M, Kadia TM, Pemmaraju N, Budak-Alpdogan T
Acta Haematol · 2026 · PMID 40159328 · Publisher ↗
INTRODUCTION: Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia that has become highly curable with advances in targeted therapy. However, central nervous system (CNS) involvement is exce...
INTRODUCTION: Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia that has become highly curable with advances in targeted therapy. However, central nervous system (CNS) involvement is exceedingly rare in APL and presents significant therapeutic challenges due to the limited penetrance of standard therapies across the blood-brain barrier (BBB). While APL is traditionally managed without chemotherapy, cases with CNS involvement require a multimodal approach for effective disease control. CASE PRESENTATION: We present a unique case of a 31-year-old male with de novo APL and CNS involvement at the presentation, including a clival mass. The patient was successfully treated with a combination of systemic chemotherapy, intrathecal chemotherapy, and craniospinal irradiation, leading to durable remission. CONCLUSION: This case highlights the rarity of CNS involvement in APL and underscores the importance of a multidisciplinary approach in its management. Additionally, it emphasizes the need to address logistical barriers to treatment to achieve optimal patient outcomes.
Acquired FX Deficiency in Multiple Myeloma without Concomitant Amyloidosis: A Rare Case Report.
Gat R, Trestman S, Kirgner I
Acta Haematol · 2026 · PMID 40159294 · Full text
<p>Introduction: Acquired factor X (FX) deficiency is a rare coagulopathy. Occurrences in plasma cell dyscrasias (PCDs) independent of amyloid light-chain amyloidosis are exceedingly rare. Case Presentation: This case re...
<p>Introduction: Acquired factor X (FX) deficiency is a rare coagulopathy. Occurrences in plasma cell dyscrasias (PCDs) independent of amyloid light-chain amyloidosis are exceedingly rare. Case Presentation: This case report presents a rare occurrence of acquired FX deficiency in a patient with multiple myeloma (MM) without concomitant amyloidosis. The patient, a 64-year-old male with prior diagnosis of smoldering MM, presented with abdominal pain and chronic bloody diarrheas and was diagnosed with absolute FX deficiency. Despite initial suspicion of amyloidosis, subsequent investigations ruled out its presence. Treatment with anti-myeloma therapy and supportive measures resulted in the normalization of coagulation parameters. Conclusion: This case underscores the importance of considering acquired FX deficiency in PCD patients presenting with coagulopathy even in the absence of amyloidosis. </p>.
Mind-Body Intervention in Chronic Lymphocytic Leukemia during the Watch-and-Wait Phase: Benefits Linked to Intervention Duration.
Shapira S, Mizrahi B, Hirschberger N … +3 more , Rabinowicz N, Zoref-Lorenz A, Flaks-Manov N
Acta Haematol · 2026 · PMID 40127631 · Publisher ↗
INTRODUCTION: Mind-body interventions (MBIs) are therapeutic practices that target the interactions between cognitive, emotional, and physiological systems to influence health outcomes. Previously, we demonstrated that M...
INTRODUCTION: Mind-body interventions (MBIs) are therapeutic practices that target the interactions between cognitive, emotional, and physiological systems to influence health outcomes. Previously, we demonstrated that MBI prolonged lymphocyte doubling time and treatment-free survival (TFS) in treatment-naïve chronic lymphocytic leukemia (CLL) patients during the watch-and-wait phase. In this follow-up study, we investigated the long-term effects of MBI on TFS after the intervention ceased. METHODS: Sixty participants from the initial study (34 who received intervention vs. 26 controls) were followed for an additional period of 20 months. TFS was assessed from the end of the intervention to the initiation of CLL therapy or death, using Kaplan-Meier analysis and the log-rank test. RESULTS: By the end of the follow-up, 9 participants who previously received MBI and 6 controls initiated CLL treatment. No significant difference in TFS was found between the groups (log-rank test, p = 0.65). CONCLUSION: While MBI provided a clear advantage as long as it continued, our follow-up analysis suggests this effect diminishes after the intervention ends. Continuous or repeated MBI may be necessary for sustained improvements in TFS.
A Bibliometric Analysis of Immunotherapy in Diffuse Large B-Cell Lymphoma from 2004 to 2024.
Wu Y, Chen X, Liu Y … +5 more , Zhao Y, Luo L, Mi Q, Wen X, Huang C
Acta Haematol · 2026 · PMID 40122025 · Publisher ↗
INTRODUCTION: Immunotherapy in DLBCL (diffuse large B-cell lymphoma) disease has become an active research area with great value and potential. However, bibliometric research in this area is still sparse. Through bibliom...
INTRODUCTION: Immunotherapy in DLBCL (diffuse large B-cell lymphoma) disease has become an active research area with great value and potential. However, bibliometric research in this area is still sparse. Through bibliometric analysis, we aimed to visualize the research hot spots and trends of immunotherapy in DLBCL disease to help understand the future development of basic and clinical research. METHODS: The Web of Science Core Collection database was searched for articles and reviews related to the immunotherapy of DLBCL from 2004 to 2024. VOSviewers, CiteSpace, and the R package "bibliometrix" were used to conduct the bibliometric analysis. RESULTS: A total of 662 articles were included. The number of immunotherapy treatments in DLBCL increased year by year. The publications came from 55 countries, led by the USA and the People's Republic of China, and 1,349 institutions, with the leading research institutions being The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Leukemia & Lymphoma is the journal with the most research, and Blood is the journal with the most co-citations. We identified 4,833 authors, among which Young and Ken H. had the most significant articles, while Neelapu S.S. had the largest number of co-citations. After analysis, the most common keyword is CAR T (CAR T cells: chimeric antigen receptor T-cell immunotherapy, a current and developing area of research. CONCLUSIONS: This is the first bibliometric study to comprehensively summarize research trends and advances in immunotherapy in DLBCL disease. This information will provide a reference for researchers and healthcare providers in immunotherapy research by clarifying recent research frontiers and hot spots such as CAR T cells, bispecific antibodies, and so on.
The Effect of T-Lymphocyte Subgroups at Diagnosis on the Prognosis of Chronic Lymphocytic Leukemia.
Seyithanoglu D, Seyithanoglu D, Sert EN … +4 more , Ozbalak M, Mastanzade M, Erdem S, Yenerel MN
Acta Haematol · 2025 · PMID 40096833 · Full text
UNLABELLED: <p>Introduction: Changes in the number and functional capacity of T lymphocytes have been reported in chronic lymphocytic leukemia (CLL) patients. The aim of this study was to examine the prognostic significa...
UNLABELLED: <p>Introduction: Changes in the number and functional capacity of T lymphocytes have been reported in chronic lymphocytic leukemia (CLL) patients. The aim of this study was to examine the prognostic significance of T-lymphocyte subgroups in CLL patients. METHODS: Eighty-three previously untreated patients were retrospectively enrolled and flow cytometry results at diagnosis were examined. No difference was found in T-lymphocyte parameters according to age, gender, and disease stage. RESULTS: The CD4 and CD7 percentages, CD4/MBC (malignant B cell), CD8/MBC, and CD7/MBC values at diagnosis were significantly lower in patients with a progressive disease. T-lymphocyte percentages were significantly lower in deceased patients. In the univariate regression model, T-lymphocyte percentages, T-lymphocyte/MBC ratios, HLA-DR+ percentage, Rai stage (intermediate + high risk), Binet stage (B+C), and beta-2 microglobulin level had significant effects on both progression-free survival (PFS) and overall survival (OS); treatment status (yes) had a significant effect only on PFS, while age at diagnosis (≥65 years) had a significant effect only on OS. In the multivariate regression model, Rai stage, CD7/MBC ratio, and treatment status (yes) had a significant effect on PFS; Rai stage and CD8/MBC ratio had a significant effect on OS. CONCLUSION: Lower T-lymphocyte/MBC ratios at diagnosis could be a marker for higher risk of CLL progression. </p>.
Hematological Evaluation and Management of Menorrhagia in Adolescents: Lessons from Adolescent Heavy Menstrual Bleeding Clinics.
Levy-Mendelovich S, Benish M, Yarhi AS … +7 more , Budnik I, Klieger C, Gruber N, Harel Y, Kenet G, Barg AA, Levy-Mendelovich S
Acta Haematol · 2025 · PMID 40090319 · Full text
UNLABELLED: <p>Introduction: Heavy menstrual bleeding (HMB) poses a significant concern among adolescents and can arise from bleeding disorders. This study aimed to compare the clinical presentations and treatment of ado...
UNLABELLED: <p>Introduction: Heavy menstrual bleeding (HMB) poses a significant concern among adolescents and can arise from bleeding disorders. This study aimed to compare the clinical presentations and treatment of adolescents with HMB, distinguishing those with and without an underlying bleeding disorder. METHODS: We conducted a retrospective analysis of adolescent patients presenting with HMB during 2014-2022 at specialized hematology-adolescent clinics in two tertiary referral hospitals in Israel. The study was approved by the Institutional Review Boards. RESULTS: Seventy-seven adolescents underwent evaluation for HMB, and 19 of them were diagnosed with various bleeding disorders: platelet aggregation defects (5), immune thrombocytopenia (1), Glanzmann thrombasthenia (1), VWD type 1 (5), type 2 A (1), type 3 (3), and coagulation factor deficiencies (3). Notably, 38 patients (49%) were hospitalized. A higher bleeding score (BAT) significantly correlated with hospitalization and a lower hemoglobin level (p < 0.001). We did not find any significant differences between adolescents with or without a bleeding disorder regarding age of presentation, time from menarche, BAT, hemoglobin, or platelet count. CONCLUSION: Our findings revealed the clinical presentations and treatments of adolescents with HMB are similar, regardless of the presence of a bleeding disorder. This emphasizes the importance of thorough evaluation in all adolescents presenting with HMB. </p>.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe